Transcatheter Therapeutics Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA combo products forum: Agency is expected to host a public meeting this fall to discuss its review of combination products, FDA Office of Drug Evaluation Cardio-Renal Products Division Director Doug Throckmorton reports. The collaboration between CDRH and the Center for Drug Evaluation and Research to review drug-eluting stents has been "a model" for future inter-center collaboration, Throckmorton reports at a Sept. 25 TCT FDA "town hall" meeting." In the meantime, the agency is seeking input from stakeholders on how the review of combination products can be improved and clarified...
You may also be interested in...
Optical Imaging Indicates Multifocal Approach To Coronary Lesion Treatment
Systematic treatment of coronary inflammation should accompany localized treatment of vulnerable plaques in prevention strategies for myocardial infarction, according to an analysis by Massachusetts General Hospital's Wellman Center for Photomedicine
Optical Imaging Indicates Multifocal Approach To Coronary Lesion Treatment
Systematic treatment of coronary inflammation should accompany localized treatment of vulnerable plaques in prevention strategies for myocardial infarction, according to an analysis by Massachusetts General Hospital's Wellman Center for Photomedicine
Kensey Nash Reviewing TriActiv Distal Protection Marketing Options
Completion of the 50-center, 800-patient, randomized U.S. PRIDE trial of the TriActiv distal protection system in coming months will clear the way for a 510(k) submission by year-end, Kensey Nash says